What we do …
Chronic liver diseases, including liver steatosis, cirrhosis and cancer, affect millions of human beings and are leading causes of death and liver transplantation worldwide. They are therefore grave public health problems and consequently a field of considerable pharmaceutical interest. Worryingly, the incidence of liver disease is dramatically rising due to the global epidemics of obesity/overweight that has become a major socioeconomic challenge, affecting both adults and children.
In our group, we aim to dissect the mechanisms underpinning chronic liver disease and cancer and the link obesity-liver disease, with a particular interests in unraveling how dysregulated posttranscriptional reprogramming (leading to aberrant protein expression) facilitates disease progression and aggravation. The ultimate goal is to identify novel therapeutic targets that help design new and more effective treatments. We use a combination of mouse models and cell-based models (human and mouse), knockout mice, high-throughput genomic approaches, and basic molecular and cellular biology.
We are currently interested in studying the following questions:
1-Which is the role of translational control of gene expression in liver disease and cancer?
To understand the molecular mechanisms involved in the development and progression of liver disease and cancer, with a focus on the aberrant reprogramming of posttranscriptional regulatory patterns. This will allow us to identify new therapeutic targets and diagnostic biomarkers for the treatment of patients.
2-What is the significance and underlying mechanisms linking obesity with liver disease and cancer?
To decipher mechanisms underpinning the detrimental impact of obesity in liver disease and cancer. This knowledge is crucial for advancements in treatment strategies for patients.